Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge

Journal of the American College of Cardiology

Volumn 43, Issue 11, 2004, Pages 2036-2043

  Butler, Javed ^a,b,c,d   Arbogast, Patrick G ^a   Daugherty, James ^a   Jain, Manoj K ^c   Ray, Wayne A ^a   Griffin, Marie R ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Center for Healthcare Quality   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ACEI; angiotensin receptor blocker; angiotensin converting enzyme inhibitor; ARB; Centers for Medicare and Medicaid Services; CMS; EF; ejection fraction; hazard ratio; heart failure; HF; HR; JCAHO; Joint Commission for Accreditation of Healthcare Organizations

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ANGIONEUROTIC EDEMA; AORTA STENOSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG UTILIZATION; FEMALE; HEALTH CARE QUALITY; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; URTICARIA;

AFTERCARE; AGED; AMBULATORY CARE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENCHMARKING; COHORT STUDIES; DRUG UTILIZATION REVIEW; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MEDICARE; MIDDLE AGED; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; TENNESSEE;

EID: 2542439527     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.01.041     Document Type: Article

References (27)

1. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 273:1995;1450-1456
2. Yusuf S., Pfeffer M.A., Swedberg K.S., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction The charm-preserved trial. Lancet. 362:2003;777-781
3. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153
4. Clark M.J. Jr., Sterrett J.J., Carson D.S. Diabetes guidelines A summary and comparison of the recommendations of the american diabetes association, veterans health administration, and american association of clinical endocrinologists. Clin Ther. 22:2000;899-910
5. Aram V., Chobanian G.L., Henry R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The jnc 7 report. JAMA. 289:2003;2560-2571
6. Konstam M.A. Systolic and diastolic dysfunction in heart failure? Time for a new paradigm. J Card Fail. 9:2003;1-3
7. Hunt S.A., Baker D.W., Chin M., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 104:2001;2996-3007
8. Jencks S.F., Cuerdon T., Burwen D., et al. Quality of medical care delivered to Medicare beneficiaries A profile at state and national levels. JAMA. 284:2000;1670-1676
9. JCAHO Overview of Heart Failure Core Measure Set. Available at: http://www.jcaho.org/pms/core+measures/hf_overview.htmf. Accessed June 16, 2003.
10. Quality Improvement Organizations: Statement of Work. Available at: http://cms.hhs.gov/qio/2.asp. Accessed June 16, 2003.
11. Get With The Guidelines. American Heart Association. Available at: http://www.americanheart.org/presenter.jhtml?identifier=1165. Accessed June 16, 2003.
12. Guidelines Applied in Practice. American College of Cardiology. Available at: http://www.acc.org/gap/gap. Accessed June 16, 2003.
13. Hospital Quality Information Initiative. Available at: http://www.cms.hhs.gov/quality/hospital/hqii.asp. Accessed June 16, 2003.
14. Stafford R.S., Saglam D., Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med. 157:1997;2460-2464
15. Philbin E.F., Andreaou C., Rocco T.A., et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 10:1996;832-838
16. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med. 157:1997;1103-1108
17. Krumholz H.M., Vaccarino V., Ellerbeck E.F., et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons ≥65 years of age. Am J Cardiol. 79:1997;581-586
18. Best Hospitals. Available at: http://www.usnews.com/usnews/nycu/health/ hosptl/ranking. Accessed June 16, 2003.
19. Krumholz H.M., Parent E.M., Tu N., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Int Med. 157:1997;99-104
20. Butler J., Arbogast P.G., BeLue R., et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 40:2002;1589-1595
21. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications A cross-national study. JAMA. 279:1998;1458-1462
22. Bradley A., Bart M.D., Gattis W.A., Diem S.J., O'Connor C.M. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol. 79:1997;1118-1120
23. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 100:1999;2312-2318
24. Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675
25. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure Randomised trial - the losartan heart failure survival study, elite ii. Lancet. 355:2000;1582-1587
26. Haynes R.B., Montague P., Oliver T., McKibbon K.A., Brouwers M.C., Kanani R. Interventions for helping patients to follow prescription medications. Cochrane Database Systematic Revs. 3:2001;1-34
27. Bradley E.H., Holmboe E.S., Mattera J.A., Roumanis S.A., Radford M.J., Krumholz H.M. A qualitative study of increasing beta-blocker use after myocardial infarction. Why do some hospitals succeed? JAMA. 285:2001;2604-2611